<?xml version="1.0" encoding="UTF-8"?>
<p>Two critical community populations who should be members of the board are COVID‐19 survivors and representatives of youth groups. The median age of the population in Africa is 19.7 years, whereas in China it is 38.4 years, and in Europe it is 43.1 years.
 <fn id="dewb12283-note-1053">
  <label>53</label>
  <p>Kaseje, N. (2020, 30 March). Why Sub‐Saharan Africa needs a unique response to COVID‐19. World Economic Forum. Retrieved May 30, 2020, from 
   <ext-link ext-link-type="uri" xlink:href="https://www.weforum.org/agenda/2020/03/why-sub-saharan-africa-needs-a-unique-response-to-covid-19/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.weforum.org/agenda/2020/03/why‐sub‐saharan‐africa‐needs‐a‐unique‐response‐to‐covid‐19/</ext-link>.
  </p>
 </fn> The younger persons in Africa could play a significant role in containment of the epidemic (the low risk of young persons to COVID‐19 may be responsible for the low incidence and prevalence of COVID‐19 in the region).
 <fn id="dewb12283-note-1054">
  <label>54</label>
  <p>Ibid.</p>
 </fn> The population of survivors is large enough to provide insight into the design of trials. As of May 30, 2020, there were 39,204 COVID‐19 survivors in sub‐Saharan Africa,
 <fn id="dewb12283-note-1055">
  <label>55</label>
  <p>African Union/African CDC. (2020). Coronavirus Disease 2019 (COVID‐19): Latest updates on the COVID‐19 crisis from Africa CDC. Retrieved May 30, 2020, from 
   <ext-link ext-link-type="uri" xlink:href="https://africacdc.org/covid-19/" xmlns:xlink="http://www.w3.org/1999/xlink">https://africacdc.org/covid‐19/</ext-link>.
  </p>
 </fn> and they could be members of CABs for COVID‐19 clinical trials, as Ebola survivors were.
 <fn id="dewb12283-note-1056">
  <label>56</label>
  <p>Mugamba, S., Nanyondo, J., Millard, M., et al. (2020). Community engagement: the key to successful Ebola research. Humanitarian Exchange. 77, 26‐29.</p>
 </fn>
</p>
